Related Article
- Genes May Drive Link Between Parents’ and Children’s BMI: Study Finds
- Breastfeeding for 6 Months May Reduce ADHD Risk in Children, Study Finds
- Fact check: As Europe bakes, should you trust your sunscreen?
- US Supreme Court sides with agrochemicals giant Bayer over weedkiller cancer claims
- Heat wave: Why you should skip that cold beer or cocktail
mRNA Vaccines Protect Against Severe Infectious Diseases, Lancet Review Confirms
A comprehensive scientific review published in The Lancet has reaffirmed that messenger RNA (mRNA) vaccines are both safe and highly effective in protecting people against infectious diseases, including severe COVID-19. The analysis examined data from billions of vaccine doses administered worldwide, providing one of the strongest bodies of evidence yet supporting the technology's safety and effectiveness.
The review found that mRNA vaccines offer strong protection across a wide range of populations, including children, pregnant women, older adults, and people with weakened immune systems.
How mRNA Vaccines Work
Unlike traditional vaccines, mRNA vaccines deliver genetic instructions that prompt human cells to produce a harmless viral protein. This allows the immune system to recognize the virus and build protection without causing the disease itself.
Researchers say the technology enables vaccines to be developed and updated quickly, making it especially valuable for responding to emerging infectious diseases.
Benefits Far Outweigh Rare Risks
The international team of researchers, including experts from the University of British Columbia, the London School of Hygiene & Tropical Medicine, and Imperial College London, concluded that serious side effects remain extremely rare.
While uncommon cases of conditions such as myocarditis have been reported, the review found that the protection mRNA vaccines provide against severe illness, hospitalization, and death far outweighs the associated risks.
The findings are based on evidence from clinical trials, manufacturing quality standards, regulatory evaluations, post-vaccination surveillance, and active pharmacovigilance systems.
The findings are based on evidence from clinical trials, manufacturing quality standards, regulatory evaluations, post-vaccination surveillance, and active pharmacovigilance systems.
Lead author Anna Blakney, Assistant Professor at the University of British Columbia, said the vast amount of real-world data now available provides overwhelming confidence in the technology.
"After billions of doses, we now have an extraordinary amount of scientific evidence. This review confirms that mRNA vaccines are a safe and highly effective platform, supported by rigorous testing and continuous real-world monitoring," Blakney said.
"After billions of doses, we now have an extraordinary amount of scientific evidence. This review confirms that mRNA vaccines are a safe and highly effective platform, supported by rigorous testing and continuous real-world monitoring," Blakney said.
Future Beyond COVID-19
Although mRNA technology has been studied since the 1960s, it gained global attention during the COVID-19 pandemic, when the first mRNA vaccines were rapidly developed and deployed.
Researchers believe the platform has enormous potential beyond COVID-19. Ongoing research is exploring mRNA vaccines for diseases such as influenza, respiratory syncytial virus (RSV), and other infectious illnesses. Scientists are also investigating personalized cancer vaccines and RNA-based therapies that could transform future medical treatments.
Researchers believe the platform has enormous potential beyond COVID-19. Ongoing research is exploring mRNA vaccines for diseases such as influenza, respiratory syncytial virus (RSV), and other infectious illnesses. Scientists are also investigating personalized cancer vaccines and RNA-based therapies that could transform future medical treatments.
The review suggests that the flexibility and adaptability of mRNA technology could enable faster responses to future disease outbreaks while paving the way for more personalized healthcare.
